Get Updates

Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More


ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Study identifier: NCT01489865
Full study details on

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)


  • Histologically proven pancreatic adenocarcinoma with measurable disease
  • any number of prior therapies except prior therapy with a PARP inhibitor
  • no brain metastases or a history of previously treated brain metastases who have been treated with surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of intracranial disease and have not had treatment with steroids within 1 week of study enrollment
  • At least 14 days must have passed since all prior anti-cancer therapy
  • At least 28 days must have passed since any prior antibody-based therapies
  • At least 28 days must have passed since any prior investigational agent

Type of study:

Phase I/II


  • Veliparib orally at escalating does in Phase I and then at recommended phase II dose with standard mFOLFOX-6
  • 5-FU
  • Oxaliplatin
  • Leucovorin

Study site:

Washington DC
Georgetown Lombardi Comprehensive Cancer Center
Contact: Lisa Ley, RN MSN 202-687-6653
Contact: Karen Dorsch-Vogel, RN 202-687-6974


Page updated 06/10/13

FORCE:Facing Our Risk of Cancer Empowered